Patents Represented by Attorney John C. Demeter

Find this attorney in the Justia Lawyer Directory

  • Opioid receptor antagonists
    Patent number: 8338611
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: December 25, 2012
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Steven James Quimby
  • Potentiation of cancer chemotherapy by 7-(2, 5-dihydro-4-imidazo [1, 2-A] pyridine-3-yl-2,5-Dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine
    Patent number: 8318713
    Abstract: A method for treating gastric cancer, ovarian cancer, non-small cell lung cancer, or colorectal cancer in a patient is described, as well as pharmaceutical compositions comprising 7-(2,5-dihydro-4-imidazo[1,2-a]pyridine-3-yl-2,5-dioxo-IH-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinyl-carbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine, useful for the method and a process for preparing said compositions.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: November 27, 2012
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Thomas Albert Engler
  • Inhibitors of diacylglycerol acyltransferase
    Patent number: 8299061
    Abstract: This invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof; as well as a method for treating obesity, a method for treating diabetes, and a pharmaceutical composition.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: October 30, 2012
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Thomas James Beauchamp, Emily Jane Canada, Erik James Hembre, Jianliang Lu, John Robert Rizzo, John Mehnert Schaus, Qing Shi
  • Kappa selective opioid receptor antagonist
    Patent number: 8173695
    Abstract: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: May 8, 2012
    Assignee: Eli Lilly and Company
    Inventors: Nuria Diaz Buezo, David Lee McKinzie, Charles Howard Mitch, Concepcion Pedregal-Tercero
  • 6-substituted nicotinamide derivatives as opioid receptor antagonists
    Patent number: 8101638
    Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Miles Goodman Siegel, Russell Dean Stucky, Kumiko Takeuchi
  • Substituted tetralins as selective estrogen receptor-? agonists
    Patent number: 8093302
    Abstract: The present invention relates to novel tetralin ER-? agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-? mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.
    Type: Grant
    Filed: February 10, 2006
    Date of Patent: January 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Elizabeth Marie Thomas, Bryan Hurst Norman, Julian Stanley Kroin
  • 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
    Patent number: 8088800
    Abstract: The present invention relates to compounds of formulae (I) and (II) useful as opioid receptor antagonists for the treatment of obesity, wherein p is 0, 1, or 2; y is 0, 1, or 2; and z is 0, 1, or 2; X1 is CH2, CH, or N; to form a indolinyl, indolyl, or benzimidazole ring respectively and including applicable double bonds and/or hydrogen atoms; X2 is CH or N; R1 to R7, R3?, p, y, and z are as defined in the claims.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: January 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Dana Raε Benesh, Maria-Jesus Blanco-Pillado
  • Thienopyridines as allosteric potentiators of the M4 muscarinic receptor
    Patent number: 8071776
    Abstract: The present invention relates to selective allosteric potentiators of the Formula (I): or pharmaceutically acceptable salts thereof, for the treatment of disorders associated with M4 muscarinic receptors.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: December 6, 2011
    Assignee: Eli Lilly and Company
    Inventors: Almudena Rubio Esteban, Darryl Wayne Hilliard
  • Purine derivatives as kinase inhibitors
    Patent number: 8058425
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 15, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Purine derivatives as kinase inhibitors
    Patent number: 8022065
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 20, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, James Robert Henry, Sushant Malhotra, Jon Kevin Reel
  • Opioid receptor antagonists
    Patent number: 7902372
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: March 8, 2011
    Assignee: Eli Lilly and Company
    Inventors: Mark Donald Chappell, Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • Substituted benzopyrans as selective estrogen receptor-beta agonists
    Patent number: 7842822
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: November 30, 2010
    Assignee: Eli Lilly and Company
    Inventors: Gregory Lee Durst, Bryan Hurst Norman, Timothy Ivo Richardson
  • Crystalline variable hydrate of (S)-6-(4-(2-((3-9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt
    Patent number: 7834187
    Abstract: The present invention relates to a crystalline variable hydrate of (S)-(3-pyridinecarboxamide,6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]) -hemi-succinate, a pharmaceutical formulation containing said salt and to methods for treating obesity and/or Type 2 diabetes using said salt.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: November 16, 2010
    Assignee: Eli Lilly and Company
    Inventor: Julie Kay Bush
  • Kappa selective opioid receptor antagonist
    Patent number: 7709522
    Abstract: A selective kappa opioid receptor antagonist, (S)-3-Fluoro-4-[4-[2-(3,5-dimethylphenyl)pyrrolidin-1-yl-methyl]phenoxy]benzamide or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, and anxiety and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: May 4, 2010
    Assignee: Eli Lilly and Company
    Inventors: Nuria Diaz Buezo, Concepcion Pedregal-Tercero, David Lee McKinzie, Charles Howard Mitch
  • Substituted benzopyrans as selective estrogen receptor-beta agonists
    Patent number: 7585985
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: September 8, 2009
    Assignee: Eli Lilly and Company
    Inventors: Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
  • Diaryl ethers as opioid receptor antagonists
    Patent number: 7560463
    Abstract: Compound 5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof, useful for the treatment of irritable bowel syndrome.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: July 14, 2009
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Michael Angelo Statnick
  • Diaryl ethers as opioid receptor antagonists
    Patent number: 7531557
    Abstract: Compound 6-(2-fluoro-4-[[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl]-phenoxy)-nicotinamide, or a pharmaceutically acceptable salt thereof, is useful for the treatment of alcoholism.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: May 12, 2009
    Assignee: Eli Lilly and Company
    Inventor: Charles Howard Mitch
  • Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators
    Patent number: 7462647
    Abstract: The present invention provides a compound of the formula (I) wherein R is —H, or —C1-C4 alkyl; R1 is —H, —OH, —O(C1-C4 alkyl), —SO2(C1-C4 alkyl), or halo; X is —O—, —CH2—, or —C(O)—; X1 is —O— or —NR2—; R2 is —H or —CH3; Y is —S—, —CH2CH2—, or —HC?CH—; m is 0, 1, 2, or 3; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: December 9, 2008
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Norman Earle Hughes
  • Substituted benzopyrans as selective estrogen receptor-beta agonists
    Patent number: 7442812
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor ? agonists for treating Estrogen Receptor ? mediated diseases such as benign prostatic hyperplasia.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: October 28, 2008
    Assignee: Eli Lilly and Company
    Inventors: Gregory Lee Durst, Bryan Hurst Norman, Timothy Ivo Richardson
  • Opioid receptor antagonists
    Patent number: 7414132
    Abstract: A compound of the formula (I); wherein the variables X1 to X10, R1 to R7 including R3?, E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: August 19, 2008
    Assignee: Eli Lilly and Company
    Inventors: Marta Garcia De La Torre, Nuria Diaz Buezo, Prabhakar Kondaji Jadhav, Charles Howard Mitch, Concepcion Pedregal-Tercero